Lung Cancer
Conditions
Interventions
Group A:Single-port thoracoscopic radical resection of lung cancer was performed using the domestic Mindray 5mm ultra-fine endoscope (30-degree, 300mm standard model) thoracoscope
Group B:Single-port thoracoscopic radical resection of lung cancer was performed using the domestic Mindray 5mm ultra-fine endoscope (30 degrees, 450mm extended version) thoracoscope
Group C:Single-port thoracoscopic radical resection of lung cancer was performed using imported Storz 5mm ultra-fine endoscope (30 degrees, 300mm)
Group D:Single-port thoracoscopic radical resection of lung cancer was performed using imported Storz 10mm conventional endoscope (30 degrees, 300mm) thoracoscope
Sponsors
The Seventh Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 to 80 years old, gender not limited; 2. The maximum diameter of the nodule is less than or equal to 2cm. 3. It is manifested as a single pulmonary nodule on imaging. 4. Preoperative high-resolution chest CT indicates that the nodule is a ground-glass nodule, subsolid nodule or solid nodule. 5. Good lung function (FEV1>=0.8L, FEV1 accounts for >=50% of the predicted value), expected to tolerate sublobectomy or lobectomy; 6. WBC > = 4.0 * 10 ^ 9 / L, neutrophils > = 1.5 * 10 ^ 9 / L, and platelets > = 100.0 * 10 ^ 9 / L, hemoglobin > = 90 g/L; Normal liver and kidney function: ALT and/or AST are less than three times the upper limit of normal, and Cr is less than twice the upper limit of normal. 7. Physical condition score (ECOG) : 0 to 2 points; 8. Intraoperative freezing indicated negative resection margins and negative lymph nodes in groups N1 and/or N2. 9. Voluntarily participate and sign the informed consent form, and be able to comply with the research visit plan and other program requirements.
Exclusion criteria
Exclusion criteria: 1.Multiple nodules in the lungs; 2. Where the nodule is close to the hilum of the lung and segmentectomy or wedge-shaped resection cannot be performed; 3. Patients whose intraoperative frozen pathological reports are not NSCLC; 4. Those with distant metastasis or pleural and ascites found through preoperative imaging examinations; 5. Patients with severe impairment of heart, liver or kidney functions (heart function at grade 3 to 4, ALT and/or AST more than three times the upper limit of normal, Cr more than twice the upper limit of normal); 6. Patients with other malignant tumors or blood diseases; 7. Pregnant, planned pregnant and lactating female patients (diagnosed as early pregnancy when urine HCG>2500IU/L); 8. Any form of anti-tumor treatment was received before tumor resection, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy, etc. 9. Those who fail to give informed consent due to psychological, family, social or other factors; 10. Those who have participated in clinical trials related to other tumors within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoscopic Performance Evaluation;Total operation time;The total time for key surgical steps;Postoperative complications;Postoperative pain score (VAS score); | — |
Countries
China
Contacts
Public ContactYun Li
The Seventh Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed